A citation-based method for searching scientific literature

N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote, T Baert, I Belaroussi, A Dashora, S Olbrecht, F Planchamp, D Querleu. Ann Oncol 2019
Times Cited: 207

Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Tjoung-Won Park-Simon, Gordon Rustin, Florence Joly, Mansoor R Mirza, Marie Plante, Michael Quinn, Andrés Poveda, Gordon C Jayson, Dan Stark, Ann Marie Swart, Laura Farrelly, Richard Kaplan, Mahesh K B Parmar, Timothy J Perren. Lancet Oncol 2015
Times Cited: 364

List of shared articles

Times cited

Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington. Int J Gynecol Cancer 2021

The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Chongzhen Guo, Chengda Yan, Lianyue Qu, Rongrong Du, Jianyang Lin. Arch Gynecol Obstet 2021

The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study.
Henriette Strøm Kahr, Ole B Christiansen, Signe Juul Riddersholm, Inger L Gade, Christian Torp-Pedersen, Aage Knudsen, Ole Thorlacius-Ussing. J Thromb Haemost 2021

Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Ionut-Gabriel Funingana, Marika A V Reinius, Angelica Petrillo, Joo Ern Ang, James D Brenton. Semin Cancer Biol 2021

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Camilla Nero, Giuseppe Vizzielli, Domenica Lorusso, Eleonora Cesari, Gennaro Daniele, Matteo Loverro, Giovanni Scambia, Claudio Sette. J Exp Clin Cancer Res 2021

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, Domenica Lorusso. Cancers (Basel) 2021

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria,[...]. Int J Gynecol Cancer 2021

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021

The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers.
Silvana Talisa Wijaya, Natalie Yl Ngoi, David Sp Tan. Best Pract Res Clin Obstet Gynaecol 2021

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci,[...]. Int J Gynecol Cancer 2021